logo
Doctor shares shocking reason at US Senate hearing on why heart attacks have become so common in people under 40

Doctor shares shocking reason at US Senate hearing on why heart attacks have become so common in people under 40

Time of India15-07-2025
Until a few years ago, heart attacks were something many associated with people in their 60s or older. But things are changing, and not for the better. More and more young adults, some as young as their late 20s or early 30s, are now falling victim to heart attacks.
Recently, a prominent US-based cardiologist, Dr Peter McCullough, shared disturbing findings that shed light on this alarming trend.
At a US Senate hearing held on May 21, 2024, Dr McCullough, alongside other top experts, revealed critical insights into what might be fueling this early onset of heart disease. What followed was a deeply unsettling, evidence-based discussion that called attention to some uncomfortable truths.
What the headlines say: 'Lifestyle choices are to blame'
It's common to hear that poor lifestyle habits, like junk food, lack of exercise, smoking, and alcohol, are behind the spike in heart attacks among younger individuals. While these certainly play a role,
Dr McCullough
emphasised that something deeper and more systemic may be at work.
There's growing clinical concern that external medical interventions, such as repeated exposure to mRNA-based COVID-19 vaccines, may also contribute to cardiac stress in certain people, especially young men.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Đây có thể là thời điểm tốt nhất để giao dịch vàng trong 5 năm qua
IC Markets
Tìm hiểu thêm
Undo
This doesn't discount lifestyle factors but suggests that the risk picture might be more complex than previously believed.
The hidden role of Myocarditis in young hearts
Dr McCullough and his peers raised a critical point: a condition called myocarditis, inflammation of the heart muscle, has been underreported and downplayed. While mild cases may resolve, in some individuals, myocarditis may progress silently and cause severe damage, increasing the chances of a sudden cardiac event.
A major autopsy-based study presented during the Senate hearing linked 74% of unexpected post-vaccine deaths to complications from myocarditis. These cases weren't always detected during routine clinical checks. What's more chilling is that many of the affected individuals were young and otherwise healthy.
Watch for chest discomfort, shortness of breath, sweating, or pain in the jaw, back, or arms. In others, look for signs like clutching the chest or sudden collapse. Women and diabetics may show subtle signs like nausea or fatigue.
The overlap between COVID, vaccines, and cardiac stress
There's a tendency to attribute sudden deaths or strokes in young people to long COVID, stress, or even gym workouts.
However, experts like Dr McCullough argue that the overlap of COVID infection plus repeated vaccine boosters might be causing an immune overreaction in certain individuals.
When an mRNA vaccine is followed by a COVID-19 infection, it may amplify inflammatory responses in the body, especially around the heart. This "double-hit" effect can go unnoticed but may increase the risk of cardiac complications, including rhythm disturbances and blood clots.
This isn't a call to reject vaccines or ignore medical advice. It's time to focus on both prevention and informed decision-making. That includes monitoring for early symptoms of heart strain (like chest discomfort, palpitations, or shortness of breath), prioritising cardiac check-ups in young adults with unexplained fatigue, and understanding that heart health today requires more than the traditional advice of 'eat better and move more.
'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Calicut varsity ties up with coop. tech company to develop supercapacitors
Calicut varsity ties up with coop. tech company to develop supercapacitors

The Hindu

time29 minutes ago

  • The Hindu

Calicut varsity ties up with coop. tech company to develop supercapacitors

The Advanced Materials Research Lab at the University of Calicut has partnered with a Parappanangadi-based tech company to develop supercapacitors, the high-capacity energy storage devices, using indigenous methods. University sources said on Thursday that the collaboration with Malabar Co-op Tech was aimed at taking a breakthrough material developed entirely in India from the lab to real-world applications. The research team lead by Yahya Ismail, Professor, Department of Chemistry, and his student, Sivakrishna Prakash, had been working for the past five years on developing a new-generation energy storage material that would address some of the biggest limitations in current supercapacitors. Ideal for electric vehicles The material combines polyaniline, a highly conductive polymer, with heteroatom-doped reduced graphene oxide, a modified carbon-based nanomaterial known for its exceptional surface area and electrical conductivity. Mr. Ismail and Mr. Prakash said that what sets this invention apart was the strong chemical bondingbetween the components, which would ensure high energy storage, rapid charging, and long-term durability. 'It can store more energy than typical supercapacitors, charge very quickly, and maintain performance for thousands of cycles—making it ideal for electric vehicles, solar energy systems, and portable electronics,' they said. M.K. Jaison, project head, Malabar Co-op Tech, said that the company would provide the engineering support, infrastructure, and technology platform required to manufacture complete supercapacitor devices, facilitating a seamless transition from lab-scale innovation to real-world application. He said that this was for the first time that a cooperative sector body was getting directly engaged in the high-tech energy storage manufacturing domain. Mr. Jaison said that India currently depends on imported electrode materials, primarily from China, to assemble supercapacitors. This over-reliance on imports and limited domestic research and development have historically stifled indigenous innovation and self-reliance in this critical clean energy segment. By focussing on both material development and device manufacturing within India, the project represents a key step towards building a fully localised supply chain for advanced energy storage solutions. It is expected to open up possibilities for large-scale commercialisation, technology export, and job creation in the clean energy sector, he added.

Pakistan seeks to expand high-tech ties with China in space, nuclear fields
Pakistan seeks to expand high-tech ties with China in space, nuclear fields

Hindustan Times

time29 minutes ago

  • Hindustan Times

Pakistan seeks to expand high-tech ties with China in space, nuclear fields

Pakistan wants to deepen technological cooperation with China in the fields of space exploration and nuclear technology, a senior Pakistani minister has said. Minister Ahsan Iqbal said Pakistan plans satellite launches and aims to send astronauts to China's space station next year.(Ahsan Iqbal/ LinkedIn ) Pakistan is keen to strengthen scientific partnerships with China, including in artificial intelligence (AI) and quantum computing, Pakistan's Minister for Planning, Development and Special Initiatives Ahsan Iqbal, who was on a visit to China, told the media. "I had an opportunity to meet with the new chairman of China's nuclear authority and the space agency,' Iqbal said in a media briefing early this week, the Hong Kong-based South China Morning Post reported on Thursday. 'We also discussed how we can further strengthen our cooperation in peaceful nuclear use of technology by extending nuclear power into agriculture,' he said. Also Read: China backs Pakistan's counter terrorism efforts, says foreign minister Wang Yi Pakistan's Karachi Nuclear Power Plant Unit 3, which uses the Chinese-made Hualong One reactor, completed its final tests before going into operation, according to the report. Iqbal said China-Pakistan space cooperation included satellite launches and plans to send Pakistan's astronauts to China's space station next year. 'Later with Chinese help, we will send and land a rover on the moon that will be yet another milestone,' he said. 'Pakistan also aims to have its lunar landing or landing on the moon by 2035, and we have also sought cooperation in this field,' he said. During his visit to China, Iqbal said he had witnessed the July 31 launch of the Pakistan Remote Sensing Satellite-1 at the Xichang Satellite Launch Centre in the southwestern province of Sichuan.

Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose
Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose

Time of India

time31 minutes ago

  • Time of India

Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose

Eli Lilly's weight loss pill doesn't appear to work as well as Wall Street had hoped. The drugmaker said Thursday the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial. The result falls on the lower end of Wall Street's expectations. Shares of the company fell around 13% on Thursday, according to CNBC. Meanwhile, shares of rival Novo Nordisk, which is also working to bring an obesity pill to the market, jumped more than 7% on Thursday. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Eli Lilly, which makes the injectable drugs Zepbound to treat obesity and Mounjaro and Trulicity to treat diabetes, is among several companies chasing an effective pill form of GLP-1s. The only such pill available so far comes with strict diet restrictions and is approved to treat diabetes. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Web Search search Search Now Undo Lilly says that no food or water restrictions are needed with the experimental oral medication, orforglipron, and it can be taken any time of day. ALSO READ: Firefly Aerospace ignites Wall Street as it raises $868 million in biggest space IPO. All about SpaceX rival Live Events Eli Lily on daily GLP-1 pills Eli Lilly announced that its new orforglipron pill led to an average weight loss of up to 27.3 pounds, based on results from the first of two Phase 3 trials involving over 3,100 overweight or obese adults. "With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments," Kenneth Custer, an executive vice president and president of Lilly Cardiometabolic Health, said in a statement. "With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need." ALSO READ: VA terminates major union contracts and it will impact over 400,000 federal workers. What's at stake for you? Investors had high hopes that Lilly's pill, orforglipron, would match the effectiveness of Novo Nordisk's blockbuster weight-loss injection, Wegovy. In key trials, Wegovy helped users lose around 14% to 15% of their body weight — slightly below the weight loss seen with Lilly's competing shot, Zepbound. 'There was hope that this would be a wonder drug,' BMO analyst Evan Seigerman said of Lilly's pill. 'What this shows to me is that it's still a good drug, but it's bound by the limitations of being a GLP-1.' Eli Lilly said that all adults participating in its Phase 3 trials experienced weight loss while taking orforglipron. Participants on the highest dose—36 mg—lost an average of 27 pounds over 72 weeks, equating to about 12% of their body weight. While this result is significant, it falls slightly short of the weight loss typically seen with some injectable treatments with the drugmaker noticing that about 10% of participants on the highest dose chose to discontinue the pill. ALSO READ: $1,702 stimulus check in August: Last chance to apply for PDF closes soon. Check key dates, eligibility, tax implication Beyond weight loss, trial participants saw improvements in cardiovascular markers, including reductions in systolic blood pressure, non-HDL cholesterol, and triglycerides. Negative side effects were similar in frequency and nature to those observed with injectable GLP-1 medications. The most commonly reported side effects were mild to moderate gastrointestinal issues such as nausea, constipation, indigestion, diarrhea, and vomiting. Eli Lilly is also evaluating orforglipron's effectiveness in adults with Type 2 diabetes. In April, the company shared that the pill may help lower hemoglobin A1C levels—a key indicator of average blood sugar over two to three months—while also supporting weight loss. Eli Lilly aims to seek global regulatory approval for its daily oral orforglipron pill by the end of 2025, positioning itself alongside rival Novo Nordisk, which is pursuing approval for an oral form of its Wegovy (semaglutide) treatment. However, federal health regulators are expected to require more comprehensive data on the drug's safety, tolerability, and effectiveness before moving forward with any potential approval.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store